You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK)附屬於研發日上展示多項在研藥進展
金斯瑞生物科技(01548.HK)公佈,旗下非全資附屬公司傳奇生物科技在10月18日研發日上,展示一系列在研製劑的初步臨牀前和臨牀資料。其中在研的自體嵌合抗原受體T細胞LB1908免疫療法,在臨牀前研究中,LB1908在細胞源性異種移植瘤(或CDX)胃腫瘤小鼠模型和CDX胰腺腫瘤小鼠模型中顯示出顯着的抗腫瘤效果。 LB2102小細胞肺癌(SCLC)項目的靶點delta-like ligand 3 (DLL3),在發現階段,LB2102 CAR表現出與靶向蛋白DLL3的強特異性結合,並無脫靶結合。體外和體內研究顯示,LB2102以靶標依賴的方式具有強大的腫瘤殺傷作用,而無脫靶細胞毒性。 LB2101肝細胞癌(HCC)和非小細胞肺癌(NSCLC)項目的靶點Glypican-3 (GPC3)在發現階段,LB2101 CAR表現出與目標蛋白GPC3的強特異性結合,並無脫靶結合。體外和體內研究顯示,LB2101以靶標依賴的方式具有強大的腫瘤殺傷作用,而無脫靶細胞毒性。 靶向CD20的異體CAR-T產品LUCAR-20S一期研究(NCT04176913)已經啓動,評估供體來源CD20靶向CAR-T細胞並做清淋處理的安全性和藥代動力學,獲得對復發或難治性CD20陽性瀰漫大B細胞淋巴瘤、濾泡淋巴瘤、套細胞淋巴瘤或小淋巴細胞淋巴瘤患者的初步療效結果。 傳奇生物還將展示公司內部的嵌合抗原受體(CAR)自然殺傷(NK)細胞治療平臺。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account